Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele-Milan, Italy.
Cardio Center, IRCCS Humanitas Research Hospital, 20089 Rozzano-Milan, Italy.
Rev Cardiovasc Med. 2022 Feb 22;23(2):76. doi: 10.31083/j.rcm2302076.
Tricuspid regurgitation (TR) has a considerable prevalence in the overall population, that further increases in selected categories of patients. Three morphologic types of TR prevail, namely primary, secondary and atrial TR, mostly, but not always, occurring in different subsets of patients. Recent evidences demonstrate a negative impact of TR on outcomes, irrespective of etiology and even when less than severe in grading. Unfortunately, current surgical standards are void of strong prospective evidence of positive impact on clinical outcomes. While on one hand recent advances in diagnosis and risk stratification of patients with TR are shedding light onto the population that may benefit from intervention and its appropriate timing, on the other hand the arrival on stage of percutaneous treatment options is widening even more the therapeutic options for such population. In this review we will address and discuss the available evidence on the prognostic impact of TR in different clinical contexts encountered in practice.
三尖瓣反流（TR）在总人口中具有相当高的患病率，在某些特定患者群体中进一步增加。TR 主要有三种形态类型，即原发性、继发性和心房性 TR，但并非总是如此，它们大多发生在不同的患者亚组中。最近的证据表明，TR 对预后有负面影响，无论病因如何，即使在分级中不严重也是如此。不幸的是，目前的外科标准缺乏对临床结局产生积极影响的强有力的前瞻性证据。一方面，TR 患者的诊断和风险分层的最新进展揭示了可能从干预及其适当时机中获益的人群，另一方面，经皮治疗选择的出现也为这类人群扩大了治疗选择。在这篇综述中，我们将讨论并讨论 TR 在实践中遇到的不同临床环境中的预后影响的现有证据。
